2018 drug industry statistics

Hardman & Co Report Report Downloads

Although the focus of Hardman & Co is predominantly on companies in the small- to mid-sized market capitalisation range, when writing research reports, it is important to position them relative to the industry in which they operate. Apart from Japanese companies, all the major global pharmaceutical companies have reported full-year results for 2018 over the past few weeks; therefore, we have taken the opportunity to update our industry database and generate the first cut of global rankings for 2018. For an industry that requires a long investment cycle – it still takes, on average, 10 years from discovery to launch of a new drug – decisions made many years ago have important consequences on current financial results. Therefore, looking back at operational performance over 20 years reveals how different company strategies have panned out.

Our pharmaceutical database
Whatever the size of a company, it is imperative to outline the commercial market opportunity that the company’s (often disruptive) technology is targeting. While such work requires significant research, it often constitutes only a very small part of the overall report. It does, however, have the advantage of providing us with a global commercial dataset that is reliable and independent of third-party input.

Pharmaceutical sales are defined as anything that requires a prescription (Rx) and specifically excludes Over-The-Counter (OTC) and consumer products. It is important to note that this does include generic drugs and biosimilars, both of which require a prescription.

Our database of pharmaceutical companies and drugs goes back to 1985. All the data are based on net ex-factory sales reported by companies, and exclude all discounts and allowances, returns, chargebacks and government rebates, such as Medicaid and Medicare. All reported numbers are converted into USD at daily average exchange rates – available from the Bank of England website. These data have, therefore, been compiled consistently and with great care, so that direct comparisons among companies can be made.

We have based our analysis on the annual accounts of ca.40 multinational companies, which cover ca.75% of the global pharmaceutical market and ca.90% of the US drug market. Market share statistics have been calculated from our provisional estimate for the global prescription drug market, which cannot be finalised until after the Japanese drug companies and Boehringer Ingelheim report in May 2019.

There does not appear to be a profile here yet (if this your your plc please get in touch)
Facebook
Twitter
LinkedIn
Hardman & Co

More articles like this

hVIVO plc

hVIVO Investor Conference

hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,

Tirupati Graphite plc

Tirupati Graphite: Business Development Update

Tirupati Graphite PLC (LON:TGR) is a fully integrated specialist graphite and graphene producer, with operations in Madagascar and India. The Company is delivering on this strategy by being fully integrated from mine to graphene. Its global

Fidelity Special Values

FTSE 100 on track for positive March quarter end

UK’s FTSE 100 was set for a positive end to the March quarter and touched fresh highs on Thursday after a rally last week, bolstered broadly by miner and bank stocks on the last trading day

Silver futures rise on spot demand

Silver prices on Wednesday marginally rose Rs 18 to Rs 74,536 per kilogram in futures trade as participants widened their bets on a firm spot demand. On the Multi Commodity Exchange, silver contracts for May delivery